In The News

Sep 1, 2026 Pharma Journalist: Kazia Therapeutics Raises $40 Million to Advance Paxalisib Trials

Sep 1, 2026 Pharmaceutical Technology: Kazia Closes Oversubscribed Offering to Fund Paxalisib’s Clinical Development

Aug 28, 2026 AllSci: Kazia Touts 100% Clinical Benefit Rate for Paxalisib in Early-Stage TNBC Study

Aug 28, 2026 BioSpectrum Asia: Kazia Reports 100% Clinical Benefit Rate in Initial Patients with Advanced Triple-Negative Breast Cancer

Aug 28, 2026 Pharmacally: Paxalisib Shows Early Clinical Activity in Advanced TNBC

Aug 28, 2026 Cancer Network: Paxalisib Achieves 100% Clinical Benefit Rate in Metastatic TNBC

Jul 16, 2026 Authority Magazine: Meet The Disruptors: Dr John Friend Of Kazia Therapeutics On The Five Things You Need To Shake Up Your Industry

Jul 2, 2026 American Journal of Managed Care: Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer

May 29, 2026 Base to Base Biotech Podcast 61: Making Tumours Visible, and Taking on Tough Challenges

Feb 11, 2025 QIMR Berghofer Podcast: World First Clinical Trial to Test New Approach to Target Triple Negative Breast Cancer

Jan 30, 2025 Skynews: Breakthrough Research by QIMR with Kazia Therapeutics to Develop Breast Cancer Drug

Dec 2, 2024 BioSpace: Biopharma Takes on Deadly Brain Cancer After Decades of Failure